Science
Mechanism of Action
Palmitoyl Tripeptide-53 Amide acts as a precise antagonist of the Wnt signaling pathway. This action facilitates β-catenin degradation, thereby suppressing Microphthalmia-associated Transcription Factor (MITF) expression. By inhibiting MITF, it effectively reduces melanogenesis, leading to a more uniform and radiant complexion. Furthermore, it modulates the Wnt/JNK signaling pathway to suppress the production of proinflammatory cytokines such as TNFα and interleukin-1β, offering significant skin-soothing benefits.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
The Formula
Formulation
Stability
The palmitoyl and amide modifications enhance the peptide's inherent stability within cosmetic formulations, ensuring prolonged efficacy throughout a product's shelf life.
Safety
Safety Profile
While formal safety assessments from CIR or SCCS are not yet available for Palmitoyl Tripeptide-53 Amide, general information regarding palmitoyl tripeptides suggests a low potential for irritation at typical cosmetic concentrations. However, individual allergic reactions are always possible, and comprehensive safety data specific to this peptide is still pending review.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Palmitoyl Tripeptide-53 Amide presents a valuable, multi-functional approach to achieving a brighter, more even, and soothed complexion through its targeted modulation of melanogenesis and inflammatory pathways, though specific clinical dose-response data is currently limited.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources